Literature DB >> 14741159

Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.

Monica E Embers1, Lynn R Budgeon, Timothy D Culp, Cynthia A Reed, Martin D Pickel, Neil D Christensen.   

Abstract

A peptide derived from the human papillomavirus type 16 (HPV-16) minor capsid protein, L2, has previously been reported to induce cross-neutralizing antibodies in mice. In this report, four HPV L2 peptides, including the HPV-16 peptide and its HPV type 6 and 11 homologues, along with extended peptides containing a conserved set of amino acids, were used to immunize rabbits and mice. Antibody responses were evaluated for specificity and ability to neutralize viral infection in vitro with a quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR) assay. All peptide immunizations resulted in cognate and cross-peptide reactivity, but this did not translate equally into recognition of full-length protein, VLP, or neutralization of virus in vitro. This report provides the first evidence of cross-neutralization of authentic HPV by antiserum to L2 peptides. Comparison of the anti-peptide serum reactivity, especially with regard to neutralization of virus, indicates that the extended peptides may offer more potential to induce adequate responses for cross-protective immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741159     DOI: 10.1016/j.vaccine.2003.08.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Study of infectious virus production from HPV18/16 capsid chimeras.

Authors:  Horng-Shen Chen; Jennifer Bromberg-White; Michael J Conway; Samina Alam; Craig Meyers
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

2.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

3.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Authors:  Ratish Gambhira; Balasubramanyam Karanam; Subhashini Jagu; Jeffrey N Roberts; Christopher B Buck; Ioannis Bossis; Hannah Alphs; Timothy Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 5.  Replication and assembly of human papillomaviruses.

Authors:  M J Conway; C Meyers
Journal:  J Dent Res       Date:  2009-04       Impact factor: 6.116

6.  Arrangement of L2 within the papillomavirus capsid.

Authors:  Christopher B Buck; Naiqian Cheng; Cynthia D Thompson; Douglas R Lowy; Alasdair C Steven; John T Schiller; Benes L Trus
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

7.  Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Authors:  Christina Schellenbacher; Richard Roden; Reinhard Kirnbauer
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

8.  The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection.

Authors:  Andrew W Woodham; Diane M Da Silva; Joseph G Skeate; Adam B Raff; Mark R Ambroso; Heike E Brand; J Mario Isas; Ralf Langen; W Martin Kast
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

Review 9.  Papillomavirus Infectious Pathways: A Comparison of Systems.

Authors:  Jennifer Biryukov; Craig Meyers
Journal:  Viruses       Date:  2015-08-04       Impact factor: 5.048

10.  A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.

Authors:  Xue Chen; Hongyang Liu; Ting Zhang; Yanchun Liu; Xixiu Xie; Zhirong Wang; Xuemei Xu
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.